Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZAŽ (lubiprostone) (24 mcg).

 

Feb 28, 2011
Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Cowen Conference

Feb 24, 2011
Sucampo to Release Fourth Quarter and Full Year 2010 Financial Results and to Conduct a Conference Call on March 3, 2011

Jan 13, 2011
Sucampo Announces Resignation of Chief Financial Officer